Ecallantide is a recombinant protein therapeutic that acts as a potent and selective inhibitor of plasma kallikrein. It is employed primarily in the treatment of acute attacks of hereditary angioedema (HAE) in patients with C1 inhibitor deficiency.
Chemical and Pharmacological Characteristics
- Classification: Kallikrein inhibitor; biologic (recombinant protein).
- Molecular composition: Ecallantium is a 60‑amino‑acid peptide derived from a modified version of the native human protein kallikrein inhibitor, produced in the yeast Pichia pastoris.
- Mechanism of action: By binding to plasma kallikrein, ecallantide prevents the conversion of high‑molecular‑weight kininogen to bradykinin, a vasoactive peptide responsible for increased vascular permeability and the swelling characteristic of HAE attacks. Inhibition of kallikrein thereby reduces bradykinin production and ameliorates angioedema symptoms.
Medical Use
- Indication: Acute treatment of HAE attacks in patients 12 years of age and older with hereditary angioedema due to C1 inhibitor deficiency (type I or type II).
- Administration: Delivered by subcutaneous injection. The recommended dose is a single 30 mg injection administered in the thigh or abdomen.
- Regulatory status:
- Approved by the United States Food and Drug Administration (FDA) in 2009 under the trade name Kalbitor.
- Licensed in the European Union and several other jurisdictions for the same indication.
Efficacy and Clinical Data
- Phase III clinical trials demonstrated that ecallantide achieved a statistically significant reduction in median time to symptom improvement compared with placebo. Approximately 70 % of treated patients reported meaningful relief within 4 hours of dosing.
- Long‑term safety data from post‑marketing surveillance indicate a favorable benefit‑risk profile when used for intermittent acute attacks.
Adverse Effects
- The most common adverse events are injection‑site reactions (erythema, swelling, pain).
- Anaphylaxis and hypersensitivity reactions have been reported; therefore, ecallantide is prescribed with a risk‑evaluation and mitigation strategy (REMS) program requiring administration in a medically supervised setting with monitoring for at least 2 hours after injection.
- Other reported side effects include headache, nausea, and dizziness.
Contraindications and Precautions
- Contraindicated in patients with a known hypersensitivity to ecallantide or any component of the formulation.
- Caution is advised in individuals with a history of severe allergic reactions or anaphylaxis.
Pharmacokinetics
- After subcutaneous administration, ecallantide reaches peak plasma concentrations within 2–4 hours.
- The biologic is eliminated primarily via proteolytic degradation, with an estimated terminal half‑life of approximately 2 hours.
Drug Interactions
- No clinically significant drug–drug interactions have been identified. However, concomitant use of other HAE‑specific therapies (e.g., C1‑esterase inhibitor concentrates or bradykinin‑B2 receptor antagonists) should be coordinated by a healthcare professional.
Research and Development
- Ongoing investigations explore the use of ecallantide for other bradykinin‑mediated conditions, such as acquired angioedema and certain inflammatory disorders; results are pending and have not yet led to additional approved indications.
Regulatory and Commercial Information
- Manufacturer: Takeda Pharmaceuticals (formerly The C. W. Johnson & Johnson Company).
- Trade name: Kalbitor (United States).
References
Information summarized from FDA drug approval documents, peer‑reviewed clinical trial publications, and product labeling as of the latest available updates (2024).